A company still losing money with growing sales, with elevated risk. Institutions are adding.
Going well
Sales up 216% last year
Little debt
Watch out for
About 6 months of cash left at its current burn
Losing money, losses are large next to sales
Money moves
No insider buying or selling in the last 30 days
Institutions added 43% to their holdings in the quarter ending June 2026 (9 bought, 6 sold)
Facts from SEC filings, not a recommendation.
What the price means
Price as of Oct 26
$2.90+5.5% that day
Company value
$119M
Share price times all shares
Cash vs value
7%
Cash as a share of company value
Debt vs value
2%
Debt as a share of company value
From SCNX's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.
The business over time
Last 12 quarters, from SEC filings
Sales, Jun '26
$344K
Sep '23Tap a barJun '26
Over 5 years, sales shrank about 52% a year.
What the price assumes
Your guesses, our math
Move the sliders to your own view of SCNX. Starting points are the company's recent numbers (it isn't profitable yet, so the margin starts at a 10% guess).
Sales in 5 years$0M
Profit in 5 years$0M
Price these guesses point to$0.01-100% vs $2.90 todayAbout -68% a year, before dividends
Simple math on your guesses, not a forecast or a price target. Real results depend on many things these sliders leave out.
The checklist Warren Buffett-style investors use. Annual numbers for 2025.
2/6Weak
MissReturn on equity 15%+Earns a lot on the money owners have in the business.-55.6%
PassDebt under half of equityNot relying on borrowed money.0.03x equity
MissNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.Losses many times its sales
MissProfitable every yearSteady profits, not one good year.3 of 10 years
MissFree cash flow positiveBrings in more cash than it spends to run and grow.-$13.4M
PassGross margin 40%+Pricing power: sells for well above what it costs to make.76.8%
Revenue
$432K
+215.9% vs prior year
5-year growth
-52.1%/yr
revenue, per year
Total debt
$2.0M
0.03x equity
Current ratio
2.89x
short-term assets / bills due
From annual reports filed with the SEC. Not in this company's SEC data, so not scored: share count not growing. A checklist is a starting point for research, not a verdict.
Latest quarter
Quarter ended Jun 30, 2026
Reported Oct 19After close4:05 pm ET
From the press release
Continued Arbli sales growth, combined with REZENOPY commercial launch in August 2026 . and initial wholesale shipments, drives significant sequential revenue growth .
Arbli wholesale unit sales increased 74% sequentially, with recent institutional formulary . additions supporting continued commercial expansion .
With Arbli continuing to gain traction and REZENOPY becoming our second commercial-stage product following its August 2026 launch, we believe Scienture is well-positioned to meaningfully accelerate top-line revenue growth through the remainder of 2026 and into 2027.
The numbers below are the quarter before. The new quarter's full numbers come with the 10-Q. Read the press release ↗
Revenue
$344K
EPS
-$0.07
vs -$0.48
Op. margin
-785.6%
Gross margin
97.7%
Free cash flow
-$3.1M
Share count
+180.1%
vs a year ago
Insider rating
Last 90 days
No open-market insider buys or sells in the last 90 days.
Weekly insider trend
No trades to chart yet.
Filing buzz
Last 7 days vs normal
0/ 100
This week
0
Normal week
0.7
vs normal
0.0x
SEC filings of any kind. 50 means a normal week.
Institutional ownership
▲Accumulating+42.5%
Institutions added 42.5% to their holdings. 9 bought, 6 sold. 4 quarters of net buying in a row.
Shares held by institutions2.0M
Sep '24Jun '26
Safety check
From SEC filings
Share count growthYearly rate, last 3 years
+219.2%
Cash runwayAt last year's cash burn
7 months
Debt to equityLatest balance sheet: debt compared with what owners have
0.0x · $2.0M debt
Shares outstandingLatest reported
41M
Why high risk
Losing money, losses are large next to sales
About 7 months of cash left at its current burn
Share count growing 219.2% a year (dilution)
Exchange listing notice (a delisting warning or a move to another exchange)
Earnings reports
Last 12
Next reportAround Jan 18, 2027 (est.)Estimated from the same quarter last year
Results filedOct 19
Results filedAug 20
Results filedMay 22
Results filedMay 15, 2023
Results filedMar 27, 2023
Flags and big holders
Offerings 6 months, flags 12 months, holders 90 days